Toward the prevention of childhood B-all by maternal dietary intake of TVA - acute B-lymphoblastic leukemia ( B-all) I S the most common form of pediatric cancer and is the leading cause of death…
Active Grant Awarded Last action
- Award ID
- R01CA309034
- Recipient
-
Loyola University Of Chicago UEI RFRPFMNR8LA5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $482,764
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 4% complete
- Originally
- Place of performance
- Maywood, IL 60153, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded Loyola University of Chicago Health Sciences Campus $482,764 on September 11, 2026, under Grant R01CA309034 in the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds a project titled "Toward the Prevention of Childhood B-ALL by Maternal Dietary Intake of TVA," which studies whether maternal and neonatal intake of trans-vaccenic acid (TVA) can prevent B-cell acute lymphoblastic leukemia (B-ALL) in children. The project builds on leukemia transplantation model findings that a TVA-supplemented diet fed to pregnant mice repressed leukemia development in their pups by activating NK1.1+ cells. The study's stated hypothesis is that supplemented maternal and/or neonatal TVA enhances the tumor surveillance activity of NK1.1 cells to prevent B-ALL development. The full dollars obligated amount is $482,764. The period of performance runs from the September 11, 2026 award date through August 31, 2031, and work is performed in Maywood, Illinois 60153. The program's stated purpose is identifying cancer risks and risk reduction strategies and developing mechanisms for cancer prevention. The source does not identify any sub-recipients for this award.
Description
Toward the prevention of childhood B-all by maternal dietary intake of TVA - acute B-lymphoblastic leukemia ( B-all) I S the most common form of pediatric cancer and is the leading cause of death among children . The current standard of care for children with B-all results in treatment failure in 20% of patients. These standard treatments can also lead to acute/chronic toxicities which affect almost all organs of the body and significant Y negatively affect the quality of life. The mortality rate of childhood B-all survivors is 20 times higher than that of age-matched controls. Thus, IT is urgent to develop novel strategies for preventing children from getting all in the first place. Pediatric B- all develops from hematopoietic stem/progenitor cells ( hspcs) harboring genetic abnormalities (GABS). The founder GAB for almost all pediatric B -all patients can be detected in peripheral blood (PB) and cord blood at birth, suggesting its origination in utero. Importantly S these same GAB can also DE detected in PB of 0.5-5% of healthy newborns, which is 100 times higher than the incidence of childhood B-all. Fortunately, hspcs harboring such GABS serve as pre-leukemic stem CEL LS ( plcs) and cause a mild alteration of B lineage differentiation. Plcs in the majority of carriers are eliminated earl Y I N life, most likely by immune cells. The plcs in -0.2%of carriers escape immune surveillance and evolve to become leukemia initiating cells (LICS), leading eventually to the development of B-all. Infection -induced immune stress has been determined to be one of the major drivers of the PLC-to-B-all transformation . Recently using leukemia transplantation models, we found that a trans-vaccenic acid ( TVA)-supplemented diet FED to pregnant female mice represses leukemia development in their pups by activating NK1.1 + cells. Our study suggests that the intake of supplemented maternal and/or neonatal TVA enhances the tumor surveillance activity of NK1.1 cells to prevent B-all development by eliminating plcs and LICS. We will first determine the cellular and molecular mechanisms by which TVA stimulates such anti-leukemic activity in neonates and optimize the time schedule for TVA intake. We will then use more physiological B-all models to evaluate TVA-stimulated anti-leukemic activity in childhood B-all models to evaluate TVA-stimulated anti-leukemic activity in childhood B-all initiated either from germline or somatic mutations. Furthermore, we want to assess whether TVA can induce the cytotoxic activity of NK1.1+cells from human cord blood. Although TVA is a component of normal human breast milk and has been approved as safe in adults, IT cannot be tested as a supplement in infants for disease prevention without further verification of its activity and safety. In vitro culture studies of human UCB should provide solid information allowing for the elucidation of the mechanism by which TVA activates the NK cells for mutant clone elimination. However the dynamic developmental biology of NK cells in early life can only be evaluated using in vivo animal models. Many reliable pediatric leukemia mouse models have been developed which best resemble the disease pathogenesis of leukemia in children. The biology and function of mouse and human NK cells are comparable. Success in this study will help to develop safe and reliable approaches for the prevention of many cases of childhood B-all.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $482,764 |
Quick answers
Who received award R01CA309034?
R01CA309034 was awarded to Loyola University Of Chicago by National Cancer Institute (National Institutes of Health) on September 11, 2026.
How much is award R01CA309034 worth?
$482,764 has been obligated on R01CA309034.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award